Evaluated parameters
SFChT, myopia
MYOPIA, SECONDARY, ACD
The primary outcome variables were changes in AL and SER compared to baseline. SER (sphere plus half cylinder) from the pattern of five measurements was measured at least 30 min after instillation of 2 drops of 1% cyclopentolate administered every 5 min. AL was measured by calculating the average of five measurements obtained from the same IOLMaster. The secondary outcome variables included SFChT (Spectralis OCT, Herdingberg, Germany), ACD (from IOLmaster 500) and CCP (from Pentacam). PBM therapy was administered twice a day for 3 min per session with an interval of ≥ 4 h between sessions based on the self-report of participants or their supervision. We also evaluated the subjects’ social context, such as schools, and lifestyle (e.g., outdoor time) via questionnaires.Due to the small sample size, we aimed to avoid the influence of age on different growth rates of AL. Therefore, the eligibility criteria for age were set from 8 to 12 years old. In addition, we also removed the limitation on baseline AL ≥ 24.40 mm because the myopia suppression effect is unknown for axial lengths greater than 24.40 mm.